Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 13/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | RAF1 | P04049 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1285784 | 0.72 | SYK (0.35) | KDM4ENOS1RAF1 | |
| SCHEMBL1285542 | 0.72 | PDE3B (0.34) | KDM4ERAF1 | |
| SCHEMBL1285676 | 0.72 | KDM4E (0.34) | KDM4ERAF1 | |
| SCHEMBL1286279 | 0.71 | KMO (0.49) | KDM4ERAF1 | |
| SCHEMBL1285773 | 0.71 | HTT (0.40) | KDM4ERAF1 | |
| SCHEMBL1285552 | 0.71 | NPC1 (0.44) | TRPA1 | |
| SCHEMBL1285598 | 0.69 | DRD1 (0.38) | KDM4EACACBRAF1 | |
| SCHEMBL1285450 | 0.68 | KMO (0.36) | KDM4E | |
| SCHEMBL1286182 | 0.68 | ALDH1A1 (0.33) | KDM4ERAF1 | |
| SCHEMBL202508 | 0.68 | NOS1 (0.46) | KDM4EACACBTRPA1NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952014-B2 | Pyrimidine derivatives which are CGRP—antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-10 | — | — | US | disclosed |
| US-20120088755-A1 | Novel Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088755-A1 | Novel Compounds | SLC26A4, F12, SLCO1B3 | KDM4E 4588/4885ACACB 4356/4885TRPA1 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.